HK1222557A1 - 的穩定的液體製劑 - Google Patents

的穩定的液體製劑

Info

Publication number
HK1222557A1
HK1222557A1 HK16110762.7A HK16110762A HK1222557A1 HK 1222557 A1 HK1222557 A1 HK 1222557A1 HK 16110762 A HK16110762 A HK 16110762A HK 1222557 A1 HK1222557 A1 HK 1222557A1
Authority
HK
Hong Kong
Prior art keywords
velcalcetide
amg
liquid formulation
stable liquid
stable
Prior art date
Application number
HK16110762.7A
Other languages
English (en)
Inventor
Derek Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1222557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1222557A1 publication Critical patent/HK1222557A1/zh

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16110762.7A 2013-06-28 2016-09-12 的穩定的液體製劑 HK1222557A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (en) 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide)

Publications (1)

Publication Number Publication Date
HK1222557A1 true HK1222557A1 (zh) 2017-07-07

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110762.7A HK1222557A1 (zh) 2013-06-28 2016-09-12 的穩定的液體製劑

Country Status (38)

Country Link
US (4) US9820938B2 (zh)
EP (3) EP3246017B1 (zh)
JP (1) JP6027708B2 (zh)
KR (1) KR102231957B1 (zh)
CN (2) CN105764487A (zh)
AP (1) AP2015008936A0 (zh)
AR (1) AR096773A1 (zh)
AU (1) AU2014302122B2 (zh)
CA (1) CA2916222C (zh)
CL (1) CL2015003738A1 (zh)
CR (2) CR20160061A (zh)
CY (1) CY1120811T1 (zh)
DK (1) DK3013318T3 (zh)
EA (1) EA030220B1 (zh)
ES (1) ES2633989T3 (zh)
HK (1) HK1222557A1 (zh)
HR (1) HRP20171092T1 (zh)
HU (1) HUE034209T2 (zh)
IL (1) IL243210B (zh)
JO (1) JO3817B1 (zh)
LT (1) LT3013318T (zh)
MA (1) MA38724B1 (zh)
ME (1) ME02818B (zh)
MX (1) MX2015017952A (zh)
MY (1) MY180276A (zh)
PE (2) PE20160549A1 (zh)
PH (1) PH12015502816A1 (zh)
PL (1) PL3013318T3 (zh)
PT (1) PT3013318T (zh)
RS (1) RS56238B1 (zh)
SG (1) SG11201510647TA (zh)
SI (1) SI3013318T1 (zh)
TN (1) TN2015000569A1 (zh)
TW (1) TWI635874B (zh)
UA (1) UA115373C2 (zh)
UY (1) UY35636A (zh)
WO (1) WO2014210489A1 (zh)
ZA (1) ZA201600238B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02818B (me) 2013-06-28 2018-01-20 Amgen Inc Stab ilna tečna formulacija amg 416 (velkalcetida)
EA032597B1 (ru) 2014-04-03 2019-06-28 Эмджен Инк. Способ получения amg 416
WO2016154580A1 (en) * 2015-03-26 2016-09-29 Amgen Inc. Solution phase method for preparing etelcalcetide
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
JP2023525884A (ja) 2020-05-15 2023-06-19 アムジェン インコーポレイテッド 左室肥大の処置方法
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
US20240207354A1 (en) 2021-05-06 2024-06-27 Amgen Inc. Etelcalcetide formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510987A (ja) 1996-10-25 2001-08-07 アメリカ合衆国 哺乳動物のＣＤ９７αサブユニットを含む炎症および脈管形成を阻害するための方法および組成物
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ATE541582T1 (de) * 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
CN103961686A (zh) 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
CN103524623A (zh) 2007-01-19 2014-01-22 凯制药公司 肽组合物的修饰以提高稳定性和递送效率
EP2264138B2 (en) 2009-06-19 2023-03-08 The Procter & Gamble Company Liquid hand dishwashing detergent composition
RU2557654C3 (ru) * 2009-07-29 2017-07-05 Каи Фармасьютикалз, Инк. Терапевтические агенты для снижения уровней паратиреоидного гормона
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
MX337613B (es) 2011-06-08 2016-03-10 Kai Pharmaceuticals Inc Agentes terapeuticos para regular fosforo en suero.
EP2776129B2 (en) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
ME02818B (me) 2013-06-28 2018-01-20 Amgen Inc Stab ilna tečna formulacija amg 416 (velkalcetida)
EA032597B1 (ru) * 2014-04-03 2019-06-28 Эмджен Инк. Способ получения amg 416

Also Published As

Publication number Publication date
JP2016523916A (ja) 2016-08-12
TN2015000569A1 (en) 2017-04-06
NZ715403A (en) 2020-10-30
JP6027708B2 (ja) 2016-11-16
AU2014302122B2 (en) 2018-12-06
PH12015502816B1 (en) 2016-03-21
US20180080452A1 (en) 2018-03-22
LT3013318T (lt) 2017-09-11
MY180276A (en) 2020-11-26
JO3817B1 (ar) 2021-01-31
IL243210B (en) 2020-02-27
PL3013318T3 (pl) 2018-03-30
EA030220B1 (ru) 2018-07-31
CR20160061A (es) 2016-09-28
KR20160043954A (ko) 2016-04-22
HUE034209T2 (en) 2018-02-28
EA201690099A1 (ru) 2016-06-30
US20220042515A1 (en) 2022-02-10
PH12015502816A1 (en) 2016-03-21
CN105764487A (zh) 2016-07-13
EP3878433A1 (en) 2021-09-15
ME02818B (me) 2018-01-20
MA38724B1 (fr) 2017-11-30
KR102231957B1 (ko) 2021-03-25
EP3013318B1 (en) 2017-04-19
SI3013318T1 (sl) 2017-11-30
US9820938B2 (en) 2017-11-21
UA115373C2 (uk) 2017-10-25
CR20160002A (es) 2018-02-13
IL243210A0 (en) 2016-02-29
US10344765B2 (en) 2019-07-09
SG11201510647TA (en) 2016-01-28
TW201542239A (zh) 2015-11-16
EP3013318A1 (en) 2016-05-04
US20160220486A1 (en) 2016-08-04
PT3013318T (pt) 2017-07-24
WO2014210489A1 (en) 2014-12-31
DK3013318T3 (en) 2017-08-07
HRP20171092T1 (hr) 2017-10-06
BR112015032615A2 (pt) 2017-07-25
CA2916222A1 (en) 2014-12-31
CA2916222C (en) 2021-05-18
UY35636A (es) 2015-01-30
PE20210413A1 (es) 2021-03-04
US11162500B2 (en) 2021-11-02
EP3246017B1 (en) 2021-03-24
TWI635874B (zh) 2018-09-21
RS56238B1 (sr) 2017-11-30
AU2014302122A1 (en) 2016-01-21
EP3246017A1 (en) 2017-11-22
CN114376970A (zh) 2022-04-22
AP2015008936A0 (en) 2015-12-31
MA38724A1 (fr) 2017-03-31
ZA201600238B (en) 2017-05-31
CL2015003738A1 (es) 2016-12-09
PE20160549A1 (es) 2016-06-15
US11959486B2 (en) 2024-04-16
MX2015017952A (es) 2016-10-28
AR096773A1 (es) 2016-02-03
ES2633989T3 (es) 2017-09-26
US20190285074A1 (en) 2019-09-19
CY1120811T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
IL275388A (en) Liquid protein formulations containing viscosity reducing agents
HK1255605A1 (zh) 新液體組合物的增强的穩定性
HK1222557A1 (zh) 的穩定的液體製劑
LT3791860T (lt) Stabili skysta gonadotropino vaisto forma
IL241040A0 (en) Liquid formulations of rascadotril
ZA201505515B (en) Liquid menthol compositions
HK1214531A1 (zh) 穩定的靜脈內製劑
HK1209352A1 (zh) 油性液狀潔膚組合物
EP2997039A4 (en) STABILIZED LIQUID FORMULATIONS WITH RECEPTORS